Lantern Pharma | First Quarter 2022 Operating & Financial Results Conference Call

Lantern’s Q1 earnings call webinar provides updates including the anticipated launch of the Phase 2 Harmonic clinical trial for never-smokers with non-small cell lung cancer, announcement of a new LP-184 indication - brain metastases, establishment of Lantern Australian subsidiary, AI platform - RADR® surpassing 20 billion datapoints with new developments for the prediction of combination therapies, and financial updates.
Read the full press release here bit.ly/43eYbCO
#LanternPharma #LTRN #earningscall